An observational study in Colorectal Carcinoma and Lynch Syndrome, sponsored by Mayo Clinic. Recruiting at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Mayo Clinic · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States — 20 open to participants now, 32 under way, 2 of them phase 3. Colorectal Neoplasms, Hereditary Nonpolyposis · United States.
Among the 71 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, this one is the 7th largest by planned enrollment of the 29 observational ones that give a count, is one of 3 that started in 2022, is one of 29 observational ones, reaches primary completion later than 14 of the 31 other live ones, and was the 55th registered.
146 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 60 are open to participants now.
Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →20 of the 71 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States are open now. Recruiting first, the newest first:
Vividion Therapeutics, Inc. · Sites in United States, Argentina, Belgium and 19 more countries
Ages 18+
Jessica D. St. Laurent, MD · Sites in United States
Ages 18+ · Women only · Healthy volunteers
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
University of Chicago · Sites in United States
Ages 20–80
University of Colorado, Denver · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Colorectal Neoplasms, Hereditary Nonpolyposis studies recruiting now, 32 (74%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 6 · Phase 3 2
First in 1994; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 950 is above the median of 400 across 66 observational studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.
Median enrollment 174 across the 42 interventional studies, 300 across the 29 observational. Of the 32 that completed or were terminated, 7 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 71 have an industry lead sponsor. The 10 most frequent:
Mayo Clinic is the lead sponsor of 3,271 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Mayo Clinic has 1 study filed under Colorectal Neoplasms, Hereditary Nonpolyposis — fewer than ten, so there is no comparison to draw.
8 of the studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT00582296Memorial Sloan Kettering Cancer CenterMulti-Organ Screening Recommendations in Patients With Lynch Syndrome | 2026-12 |
| NCT02371135Memorial Sloan Kettering Cancer CenterMetagenomic Evaluation of the Gut Microbiome in Patients With Lynch Syndrome and Other Hereditary Colonic Polyposis Syndromes | 2027-02 |
| NCT07220239Jessica D. St. Laurent, MDMenstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome | 2027-03 |
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
| NCT05419011National Cancer Institute (NCI)Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome | 2027-07-01 |
Add all 8 to your calendar (.ics) → With an account.
Among the 71 studies in Colorectal Neoplasms, Hereditary Nonpolyposis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study collects blood and stool samples from patients with suspected or diagnosed Lynch syndrome to evaluate a deoxyribonucleic acid (DNA) screening technique for the detection of colorectal cancer in Lynch syndrome patients.
PRIMARY OBJECTIVE:
I. To determine the sensitivity and specificity of the multitarget stool DNA (mt-sDNA) 2.0 test, for colorectal neoplasia in patients with Lynch syndrome.
SECONDARY OBJECTIVE:
I. Develop a biorepository of samples (stool and blood) from patients with Lynch syndrome and early onset colorectal cancer.
OUTLINE:
Patients undergo collection of blood and stool samples no more than 90 days prior to or between 7-90 days after standard of care colonoscopy or flexible sigmoidoscopy. Patients' medical records are also reviewed.
146 studies on the registry are indexed under Colorectal Neoplasms, Hereditary Nonpolyposis; 60 are open to participants now.
This study's planned enrollment of 950 is above the median of 400 across 66 observational studies indexed under Colorectal Neoplasms, Hereditary Nonpolyposis.
Browse Colorectal Neoplasms, Hereditary Nonpolyposis studies →Mayo Clinic is the lead sponsor of 3,271 studies on the registry; 672 are open to participants now.
Of its 452 completed or terminated interventional studies of FDA-regulated products, 321 (71%) have results posted.
Compared within Colorectal Neoplasms, Hereditary Nonpolyposis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Colorectal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Adults diagnosed with Lynch syndrome or suspected Lynch syndrome or early onset colorectal cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients undergo collection of blood and stool samples no more than 90 days prior to or between 7-90 days after standard of care colonoscopy or flexible sigmoidoscopy. Patients' medical records are also reviewed.
Procedure: Biospecimen Collection · Other: Electronic Health Record Review
Undergo collection of blood and stool samples
Medical records reviewed
Sensitivity of multitarget stool deoxyribonucleic acid (mt-sDNA) 2.0 test to detect colorectal neoplasia
Results of the mt-sDNA 2.0 test will be correlated with pathology findings of patients undergoing colonoscopy to determine sensitivity of the mt-sDNA 2.0 test
Time frame: Up to 4 years
Specificity of mt-sDNA 2.0 test to detect colorectal dysplasia
Results of the mt-sDNA 2.0 test will be correlated with pathology findings of patients undergoing colonoscopy to determine specificity of the mt-sDNA 2.0 test
Time frame: Up to 4 years
Not enrolling at this site.
Started Mar 2022 (actual). Primary completion is estimated for Dec 2027, 69 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Colorectal Neoplasms, Hereditary Nonpolyposis →